Obesity (BMI ≧ 30kg/m2), Pre-diabetes (HbA1c 39-47 mmol/mol)
Conditions
Brief summary
Change in kilocalorie (kCal) consumption at ad libitum meal test, from baseline, to after 25 weeks, and after 26 weeks of semaglutide treatment, of which the last week is with the addition of pramlintide.
Detailed description
Total weight loss from baseline, after 25 weeks, and at the end of the study, both as kg and as % of total body weight, Difference in total weight loss between the phenotypes, Change in appetite and satiety sensations as measured by VAS prior to and following the meal tests performed at baseline, after 25 weeks, and at the end of the study, Change in gastric emptying rate assessed by paracetamol test performed at baseline, after 25 weeks, and at the end of the study
Interventions
DRUGPARACETAMOL
DRUGSEMAGLUTIDE
Sponsors
Esbjerg Sygehus
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Change in kilocalorie (kCal) consumption at ad libitum meal test, from baseline, to after 25 weeks, and after 26 weeks of semaglutide treatment, of which the last week is with the addition of pramlintide. | — |
Secondary
| Measure | Time frame |
|---|---|
| Total weight loss from baseline, after 25 weeks, and at the end of the study, both as kg and as % of total body weight, Difference in total weight loss between the phenotypes, Change in appetite and satiety sensations as measured by VAS prior to and following the meal tests performed at baseline, after 25 weeks, and at the end of the study, Change in gastric emptying rate assessed by paracetamol test performed at baseline, after 25 weeks, and at the end of the study | — |
Countries
Denmark
Outcome results
None listed